Samsung Bioepis Begins Recruiting Patients for Phase 3 Trial of Eculizumab Biosimilar, SB12

Samsung Bioepis has begun recruiting patients with paroxysmal nocturnal hemoglobinuria (PNH) in India for a phase 3 clinical study of its proposed eculizumab biosimilar, SB12, referencing Soliris.
Kelly Davio
August 16, 2019
Samsung Bioepis has begun recruiting patients with paroxysmal nocturnal hemoglobinuria (PNH) in India for a phase 3 clinical study of its proposed eculizumab biosimilar, SB12, referencing Soliris.

The double-blind, multicenter, crossover study will compare the efficacy, safety, pharmacokinetics (PK), and immunogenicity of SB12 with the reference eculizumab in approximately 50 patients with PNH, a rare, life-threatening disease of the blood characterized by destruction of red blood cells, presence of blood clots, and impaired bone marrow function.

Patients will be randomized to receive 600 mg of either the biosimilar or the reference eculizumab through intravenous administration every week for 4 weeks. Then, they will receive 900 mg of eculizumab for the fifth week, and 900 mg every 2 weeks until week 52. At week 26, patients initially randomized to the biosimilar will be switched to the reference, and those who initiated treatment with the reference will be switched to the biosimilar.

The primary outcome measures are hemolysis as measured by lactate dehydrogenase at week 26 in a parallel comparison and at week 52 by a crossover comparison. The study’s estimated completion date is July 2021.

In addition to PNH, the reference eculizumab is also approved by the FDA to treat atypical hemolytic uremic syndrome (a rare disease that causes abnormal blood clots to form in the small blood vessels in the kidneys), generalized myasthenia gravis (a rare, autoimmune, neuromuscular junction disorder), and, most recently, neuromyelitis optica spectrum disorder (NMOSD, a rare disorder of the central nervous system).

The European Medicines Agency’s Committee for Medicinal Products for Human Use has also adopted a positive opinion of eculizumab in for the treatment of NMOSD, and the European Commission will make a final determination on authorizing the drug for this fourth indication.

At least one other biosimilar developer is targeting the high-cost Soliris: Amgen’s proposed biosimilar, ABP 959, was recently shown in a phase 1 study to have similar PK and pharmacodynamics to the reference drug in patients 219 healthy volunteers. The proposed biosimilar also demonstrated similar safety and immunogenicity to Soliris.
 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.